A detailed history of Silverleafe Capital Partners, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Silverleafe Capital Partners, LLC holds 14,500 shares of ARQT stock, worth $206,190. This represents 0.07% of its overall portfolio holdings.

Number of Shares
14,500
Previous 26,208 44.67%
Holding current value
$206,190
Previous $409,000 50.37%
% of portfolio
0.07%
Previous 0.15%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 08, 2025

SELL
$12.59 - $16.6 $147,403 - $194,352
-11,708 Reduced 44.67%
14,500 $203,000
Q1 2025

Apr 21, 2025

BUY
$11.4 - $17.29 $298,771 - $453,136
26,208 New
26,208 $409,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $856M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Silverleafe Capital Partners, LLC Portfolio

Follow Silverleafe Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverleafe Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverleafe Capital Partners, LLC with notifications on news.